CN113583923B - Probiotic composition and application thereof in preparation of medicine for treating constipation and depression - Google Patents
Probiotic composition and application thereof in preparation of medicine for treating constipation and depression Download PDFInfo
- Publication number
- CN113583923B CN113583923B CN202111145201.7A CN202111145201A CN113583923B CN 113583923 B CN113583923 B CN 113583923B CN 202111145201 A CN202111145201 A CN 202111145201A CN 113583923 B CN113583923 B CN 113583923B
- Authority
- CN
- China
- Prior art keywords
- constipation
- probiotic
- depression
- lactobacillus
- cgmcc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 61
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 61
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 47
- 206010010774 Constipation Diseases 0.000 title claims abstract description 42
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 15
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims abstract description 13
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 13
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 12
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 12
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 12
- 238000009629 microbiological culture Methods 0.000 claims description 21
- 238000004321 preservation Methods 0.000 claims description 17
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 12
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 235000013406 prebiotics Nutrition 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 19
- 230000000994 depressogenic effect Effects 0.000 abstract description 18
- 239000000902 placebo Substances 0.000 abstract description 17
- 229940068196 placebo Drugs 0.000 abstract description 17
- 229940079593 drug Drugs 0.000 abstract description 6
- 238000012360 testing method Methods 0.000 abstract description 3
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 abstract description 2
- 229940009289 bifidobacterium lactis Drugs 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000013872 defecation Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 241000186660 Lactobacillus Species 0.000 description 5
- 229940039696 lactobacillus Drugs 0.000 description 5
- 239000000935 antidepressant agent Substances 0.000 description 4
- 229940005513 antidepressants Drugs 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 2
- 241000194036 Lactococcus Species 0.000 description 2
- 206010060926 abdominal symptom Diseases 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 208000034424 Painful defaecation Diseases 0.000 description 1
- 201000009916 Postpartum depression Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 208000020560 abdominal swelling Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000010346 psychosocial stress Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/513—Adolescentes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Nutrition Science (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a probiotic composition and application thereof in preparation of drugs for treating constipation and depression, wherein the composition comprises animal bifidobacterium lactis subspecies U9, lactobacillus paracasei L55, lactobacillus rhamnosus LL23, bifidobacterium adolescentis BQ23 and lactobacillus acidophilus RA 15. The invention carries out the probiotic intervention on the depressed patients by carrying out a random double-blind test. A total of 63 depressed patients were recruited, of which 31 patients suffered from constipation. As a result, it was found that after 8 weeks of intervention, the hamilton depression (HAMD) score of the depressed population suffering from constipation decreased to 14.2 ± 8.0, which was significantly lower than that of the placebo group (22.9 ± 9.9, P < 0.05), while the HAMD score of the depressed population without constipation was not significantly different from that of the placebo group. The probiotic composition can effectively relieve depression symptoms of co-morbid constipation depressed people.
Description
Technical Field
The invention belongs to the technical field of probiotics, and particularly relates to a probiotic composition and application thereof in preparation of a co-morbid constipation and depression medicament.
Background
Depression is a common and extremely harmful group of mental disorders. According to the report of the world health organization, the number of patients with depression in 2015 accounts for about 4.4% of the total population, and the total number of patients is as high as 3.22 hundred million. Although both depression and constipation can occur independently, studies have shown a high rate of co-morbidity between the two. 57.7% of depressed patients are reported to be accompanied by constipation symptoms, which are 1.8 times more likely to suffer from constipation than ordinary people. Patients with gastrointestinal disorders are also more prone to depression, with prevalence of depression in patients with chronic constipation reaching as high as 33%. It is seen that depression patients are large in number and have a relationship with constipation.
Drugs acting on the monoamine neurotransmitter system are currently the most widely used antidepressants in clinical use. Such antidepressants are generally capable of alleviating the symptoms of depression, but the clinical manifestations of antidepressant use vary significantly among patients. About 30% of patients use the drug with little effect, and even the same patient cannot maintain stable drug effect in different periods. There is thus a need to develop new drugs or treatments, or as an adjunct to existing antidepressant treatments.
Disclosure of Invention
The invention aims to solve the problem that the effect difference of probiotics on improving the depression symptoms of patients is large in the prior art, and provides a probiotic composition and application thereof in preparing a co-morbid constipation and depression medicament.
The purpose of the invention is realized by the following technical scheme:
the invention provides a bifidobacterium animalis subsp lactis U9, which is preserved in China general microbiological culture Collection center (CGMCC) at 11-04.2015, wherein the CGMCC is recorded in the West Lu No.1 Hospital No. 3 of the Korean area of Beijing, the institute of microbiology of the Chinese academy of sciences, the postal code 100101 and the classified name of the bifidobacterium animalis subsp lactisBifidobacterium animalis subsp. lactis,The preservation number is CGMCC number 11560.
The invention provides lactobacillus paracasei L55, which is preserved in China general microbiological culture Collection center (CGMCC) in 04.07.2017 by the China Committee for culture Collection of microorganisms, and the address is No. 3 of West Lu No.1 of Beijing City Kogyo-Yang district, the institute of microbiology of China academy of sciences, the postal code 100101, which is named as lactobacillus paracasei in classificationLactobacillus paracasei,The preservation number is CGMCC number 13996.
The invention provides lactobacillus rhamnosus LL23, which is preserved in China general microbiological culture Collection center (CGMCC) in 04.07.2017, and the address is No. 3 of Xilu-1 of Beijing city facing Yang district, the institute of microbiology of Chinese academy of sciences, zip code 100101, and the classification is named as lactobacillus rhamnosusLactobacillus rhamnosus,The preservation number is CGMCC number 13994.
The invention provides a bifidobacterium adolescentis BQ23, which is preserved in China general microbiological culture Collection center (CGMCC) in 04.07.2017, wherein the strain is prepared by the method that the strain is No. 3 of Xilu No.1 of Beijing city northwest Chen of the Korean district, the institute of microbiology of Chinese academy of sciences, a postal code of 100101, and the strain is classified and named as bifidobacterium adolescentisBifidobacterium adolescentis,The preservation number is CGMCC number 13999.
The invention provides lactobacillus acidophilus RA15, which is preserved in China general microbiological culture Collection center (CGMCC) in 04.07.2017, and the address is No. 3 of West Lu No.1 of Beijing city Kogyo-Chen-Yang district, the institute of microbiology of China academy of sciences, postal code 100101, and the classification is named as lactobacillus acidophilusLactobacillus acidophilus,The preservation number is CGMCC number 13993.
The invention provides a probiotic composition, which comprises bifidobacterium animalis subsp lactis U9, lactobacillus paracasei L55, lactobacillus rhamnosus LL23, bifidobacterium adolescentis BQ23 and lactobacillus acidophilus RA15, and the probiotic composition comprises the following components in parts by weight:
bifidobacterium animalis subsp lactis U91-10
Lactobacillus paracasei L551-10
Lactobacillus rhamnosus LL 231-10
Bifidobacterium adolescentis BQ 231-10
Lactobacillus acidophilus RA 151-10;
bifidobacterium animalis subsp lactis U9 (Bifidobacterium animalis subsp. lactis，U9) and preserved in the China general microbiological culture Collection center on 04 th month 11 in 2015 with the preservation number of CGMCC 11560;
the lactobacillus paracasei L55 (Lactobacillus paracaseiL55) is preserved in China general microbiological culture Collection center on the 07 th 04 th month in 2017, and the preservation number is CGMCC NO. 13996;
the lactobacillus rhamnosus LL 23: (Lactobacillus rhamnosusLL 23) stored in China general microbiological culture Collection center on the number of CGMCC No.13994 in 2017 at 04.07.8;
said Bifidobacterium adolescentis BQ23 (Bifidobacterium adolescentisBQ 23) stored in China general microbiological culture Collection center on the number of CGMCC 13999 in 2017 at 04.07.8;
said Lactobacillus acidophilus RA15 (Lactobacillus acidophilusRA 15) which is deposited in China general microbiological culture Collection center on the number of CGMCC 13993 on the number of 04/07 in 2017.
A probiotic product comprises the probiotic composition and a food, health product or medically acceptable carrier, adjuvant or additive.
Further, prebiotics are included in the probiotic product.
Furthermore, the probiotic product is in a dosage form of capsules, tablets, granules, powder or sustained release preparations.
Another aspect of the invention:
the probiotic composition is applied to preparation of medicines for treating constipation and depression.
Compared with the prior art, the invention has the beneficial effects that:
although the results of the prior art studies show that probiotics can improve the depression symptoms of patients, the effect of each study is very different, and the different strains are also very different. The difference in the effect of these probiotics on depression symptoms may be due, on the one hand, to the characteristics of the probiotics themselves, and although certain health-related mechanisms of action are common among various probiotic genera and species, some functions may be species-specific, even strain-specific, or may require interaction between different strains to be effective. On the other hand, depression itself is a very heterogeneous disease, the causes or pathophysiology of the attacks are different in different patients, even the causes of the attacks of the same patient at different times may be different, and both psychosocial stress and physiological stress (such as postpartum depression) may cause different pathogenesis. On the basis of the existing research, the probiotic composition obtained by compounding various probiotics can effectively relieve the depression symptoms of the depressed people who commonly suffer from constipation.
Detailed Description
The endpoints of the ranges and any values disclosed herein are not limited to the precise range or value, and such ranges or values should be understood to encompass values close to those ranges or values. For ranges of values, between the endpoints of each of the ranges and the individual points, and between the individual points may be combined with each other to give one or more new ranges of values, and these ranges of values should be considered as specifically disclosed herein.
The inventor of the invention skillfully discovers in the research process that the probiotic composition obtained by mixing five probiotics, namely bifidobacterium animalis subsp lactis U9, lactobacillus paracasei L55, lactobacillus rhamnosus LL23, bifidobacterium adolescentis BQ23 and lactobacillus acidophilus RA15, replaces the existing single probiotic to intervene in depression patients, and can effectively relieve depression symptoms of depression people suffering from constipation.
The present invention will be described in detail below by way of examples. It should be understood that the following examples are only for illustrative purposes to further explain and illustrate the contents of the present invention in detail, and are not intended to limit the present invention.
In the following examples, Bifidobacterium animalis subsp. lactococcus U9, Lactobacillus paracasei L55, Lactobacillus rhamnosus LL23, Bifidobacterium adolescentis BQ23 and Lactobacillus acidophilus RA15 were all provided by Beijing and Yiyuan Biotechnology Ltd. The five strains are all preserved in China general microbiological culture collection center. The five strains are all sourced from human intestinal tracts. Other chemicals were purchased from the normal chemical supplier and were of analytical purity.
Example 1
This example provides a probiotic composition consisting of Bifidobacterium animalis subspBifidobacterium animalis subsp. lactis) U9 Lactobacillus paracasei, Lactobacillus paracasei (II)Lactobacillus paracasei) L55, Lactobacillus rhamnosus (L)Lactobacillus rhamnosus) LL23 Bifidobacterium adolescentis (Bifidobacterium adolescentis) BQ23, and Lactobacillus acidophilus (L.) (Lactococcus acidophilus) RA15, each part of the bacterial powder weighs 2g, and the content of each bacterium is 3 multiplied by 1010CFU；
The bifidobacterium animalis subsp lactis U9 is preserved in the China general microbiological culture Collection center on 04 th month 11 in 2015 with the preservation number of CGMCC No. 11560;
the lactobacillus paracasei L55 is preserved in China general microbiological culture Collection center on the 07 th 04 th month in 2017 with the preservation number of CGMCC NO. 13996;
the lactobacillus rhamnosus LL23 is preserved in China general microbiological culture Collection center on the 07 th 04 th month in 2017, and the preservation number is CGMCC NO. 13994;
the bifidobacterium adolescentis BQ23 is preserved in China general microbiological culture Collection center on 07/04 in 2017, and the preservation number is CGMCC No. 13999;
the lactobacillus acidophilus RA15 is preserved in China general microbiological culture Collection center on the 07 th 04 th month in 2017, and the preservation number is CGMCC No 13993.
Test example
To explore the effect of the probiotic composition of example 1 on depressed persons with comorbid constipation, the test example conducted a randomized double blind trial with probiotic intervention on depressed patients.
The preparation method is completed under the supervision of the ethical committee of human research of the university of Chinese agriculture by referring to good clinical operation specifications established by the international medical regulatory agreement. The study should be performed according to the operating instructions. The protocol of the study and materials such as subject informed consent were approved by the ethical committee prior to the start of the study (ethical approval: CAUHR-2018029).
Patients participating in the study met the following conditions:
a)18 to 60 years old, with no restriction;
b) the Chinese mental disease classification scheme and the diagnosis standard (CCMD) depression attack diagnosis standard are met;
c) hamilton Depression Scale (HAMD, item 17) is not less than 8 points;
d) understand and voluntarily participate in the trial, sign informed consent.
And patients participating in this study had no:
a) there are serious or unstable body diseases such as heart, liver, kidney, endocrine, digestion, blood, etc.;
b) drug or alcohol abuse over the past year;
c) pregnant, lactating women or persons who have recently planned pregnancy
In the study, 60 depression patients were enrolled, 63 depression patients were actually enrolled, and 53 patients completed the experiment, all from Pinggu Chinese medical hospital in Beijing.
According to the screening standard, the depression patients meeting the diagnosis standard of Chinese mental disease classification scheme and diagnosis standard (CCMD) are recruited. Eligible subjects entered the group after signing an informed consent and were randomized into the probiotic group (probiotic group) and the placebo group (placebo group). Patients to be enrolled had to undergo an emptying phase of 1 week, during which time no probiotic product (including yoghurt, probiotic tablets, powders, capsules) could be consumed. After the end of the emptying period, subjects were evaluated for their degree of Depression using the Hamilton's Depression Scale (HAMD), the constipation patient self-rating Scale (PAC-SYM) was evaluated, subjects were evaluated for constipation symptoms, co-morbid constipation people were screened, and subjects' demographics, medical history, and drug treatment were recorded.
The dry expectation was 2 months total, during which the probiotic composition formed from 5 probiotic bacteria powders described in example 1, or placebo, was taken daily. During the intervention the subject will continue on a normal diet but not eat other fermented dairy products. The subject fills out the log every day, and the content comprises the taking condition and the defecation condition. At the end of the expectation, subjects were again subjected to HAMD and PAC-SYM to assess the extent of their depressive and constipation symptoms.
In order to research the influence of probiotics on constipation-related depressed people, a randomly designed blind person group experiment for the depressed people who intervene in constipation co-morbidity by using probiotics is carried out. 63 persons are eligible to participate in the study, the population is randomly divided into a probiotic group or a placebo group, and 53 persons complete the experiment. There were no significant differences in age, gender composition between the two groups (table 1). Of these 27 people met the ROME III constipation diagnostic criteria (constipation was diagnosed as two or more of: at least 25% of defecation experienced strenuous, at least 25% of defecation was dry, globular or hard, at least 25% of defecation was incomplete, at least 25% of defecation was anorectal obstructive, at least 25% of defecation needed help, less than 3 times per week).
TABLE 1 basic conditions of the population
1. Effect of probiotics on depressive symptoms of co-morbid constipation in depressed people
In the dry prognosis, the hamilton depression scale (HAMD) scores were significantly lower in the placebo and probiotic groups than in the baseline phase. During baseline, the HAMD score of the probiotic group was not different from that of the placebo group; whereas post-intervention probiotic group had a HAMD score significantly lower than placebo group (15.6 ± 8.5 vs 20.5 ± 8.6, P < 0.05) (table 2). The response of both the constipated and non-constipated depressed population to probiotic intervention was further analyzed. It can be seen that during baseline, the HAMD score was significantly higher in the constipated depressed population than in the non-constipated population, but there was no significant difference between the probiotic and placebo groups, and therefore this difference did not affect the quality of the experiment. HAMD scores were significantly lower (14.2 + -8.0 vs 22.9 + -9.9, P < 0.05) after probiotic intervention in depressed patients with comorbid constipation than in placebo, while HAMD scores were not significantly different after probiotic intervention in depressed patients without comorbid constipation than in placebo.
TABLE 2 Effect of probiotics on HAMD Depression score in Copathy Constipation Depression patients
Note: significant differences compared to placebo,P<0.05。
2. effect of probiotics on constipation symptoms of co-morbid constipation depression patients
For those who co-morbid constipation, the study also evaluated constipation symptoms using a constipation patient self-rating scale (PAC-SYM). PAC-SYM has 12 items in total and can be divided into 3 types of symptoms: abdominal symptoms (item 4, including abdominal discomfort, abdominal pain, abdominal swelling, gastrospasm), rectal symptoms (item 3, including painful defecation, burning of the rectum during or after defecation, rectal laceration or bleeding after defecation) and fecal symptoms (item 5, including feeling of incomplete defecation, difficult defecation, too little stool, exertion of force or pressure to defecate, deliberate but not defecation), are clinically common scales that can effectively assess the degree of constipation. Probiotic intervention PAC-SYM scores for patients with depressed constipation are shown in table 3. After probiotic intervention, the fecal symptom score was lower than that of the placebo group (7.17 + -4.38 vs 11.33 + -3.21, P < 0.05), which was also significantly lower than that before intervention; the abdominal symptoms and rectal symptoms of the probiotic group are not significantly different from those of the placebo group; the PAC-SYM total score of the probiotic group is significantly different from that of the placebo group (8.8 +/-5.47 vs 15.33 +/-5.03, P < 0.05). The probiotics have obvious improvement effect on constipation symptoms of depression patients with combined constipation, and particularly has obvious effect on fecal symptoms.
TABLE 3 Effect of probiotics on PAC-SYM constipation score in depressed people with comorbid constipation
Note: significant differences compared to placebo,P<0.05。
the foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (6)
1. The probiotic composition is characterized by comprising bifidobacterium animalis subsp lactis U9, lactobacillus paracasei L55, lactobacillus rhamnosus LL23, bifidobacterium adolescentis BQ23 and lactobacillus acidophilus RA15, and comprises the following components in parts by weight:
bifidobacterium animalis subsp lactis U91-10
Lactobacillus paracasei L551-10
Lactobacillus rhamnosus LL 231-10
Bifidobacterium adolescentis BQ 231-10
Lactobacillus acidophilus RA 151-10;
the bifidobacterium animalis subsp lactis U9 is preserved in the China general microbiological culture Collection center on 04 th month 11 in 2015 with the preservation number of CGMCC No. 11560;
the lactobacillus paracasei L55 is preserved in China general microbiological culture Collection center on the 07 th 04 th month in 2017 with the preservation number of CGMCC NO. 13996;
the lactobacillus rhamnosus LL23 is preserved in China general microbiological culture Collection center on the 07 th 04 th month in 2017, and the preservation number is CGMCC NO. 13994;
the bifidobacterium adolescentis BQ23 is preserved in China general microbiological culture Collection center on 07/04 in 2017, and the preservation number is CGMCC No. 13999;
the lactobacillus acidophilus RA15 is preserved in China general microbiological culture Collection center on the 07 th 04 th month in 2017, and the preservation number is CGMCC No 13993.
2. The probiotic composition according to claim 1, characterized in that the weight parts of each bacterium in the composition are the same.
3. A probiotic product, characterized in that it comprises a probiotic composition according to claim 1 or 2 and a food, nutraceutical or medically acceptable carrier, adjuvant or additive.
4. The probiotic product according to claim 3, characterized in that prebiotics are included in the probiotic product.
5. The probiotic product according to claim 3 or 4, characterized in that its dosage form comprises capsules, tablets, granules, powders or sustained release formulations.
6. Use of a probiotic composition according to claim 1 or 2 for the preparation of a medicament for co-morbid constipation and depression.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111145201.7A CN113583923B (en) | 2021-09-28 | 2021-09-28 | Probiotic composition and application thereof in preparation of medicine for treating constipation and depression |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111145201.7A CN113583923B (en) | 2021-09-28 | 2021-09-28 | Probiotic composition and application thereof in preparation of medicine for treating constipation and depression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113583923A CN113583923A (en) | 2021-11-02 |
| CN113583923B true CN113583923B (en) | 2021-12-07 |
Family
ID=78242446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111145201.7A Active CN113583923B (en) | 2021-09-28 | 2021-09-28 | Probiotic composition and application thereof in preparation of medicine for treating constipation and depression |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113583923B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114806930B (en) * | 2022-03-31 | 2022-11-22 | 青岛东海药业有限公司 | Probiotic composition and application thereof |
| CN115068508B (en) * | 2022-08-23 | 2022-11-25 | 哈尔滨美华生物技术股份有限公司 | Application of animal bifidobacterium in preparing medicament for preventing or treating depression |
| CN116064326B (en) * | 2022-12-06 | 2024-08-20 | 青岛诺和诺康生物科技有限公司 | Bifidobacterium animalis subspecies GBW8051 capable of relieving depression and application thereof |
| CN116138457A (en) * | 2022-12-14 | 2023-05-23 | 温州医科大学 | Composite nutritional composition with depression symptom relieving effect |
| CN116590205B (en) * | 2023-07-14 | 2023-10-03 | 中国农业大学 | Application of bifidobacterium animalis subspecies combination microbial inoculum in preparation of weight-losing preparation |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104224851A (en) * | 2014-08-15 | 2014-12-24 | 任发政 | Application of bifidobacterium animalis subsp. lactis CGMCC NO.9273 |
| CN106722206A (en) * | 2017-01-09 | 2017-05-31 | 广州能靓生物技术有限公司 | A kind of composition for alleviating alimentary canal malaise symptoms and/or emotional stress and products thereof |
| CN109200064A (en) * | 2017-07-07 | 2019-01-15 | 中国农业大学 | The purposes of animal bifidobacteria A6 in medicine preparation |
| CN110305820A (en) * | 2019-08-19 | 2019-10-08 | 江南大学 | Lactobacillus rhamnosus CCFM1064 and its application |
| CN110810629A (en) * | 2018-08-07 | 2020-02-21 | 中国农业大学 | Probiotic preparation and application thereof |
| CN113150993A (en) * | 2021-02-01 | 2021-07-23 | 漯河微康生物科技有限公司 | Low-temperature spray drying preparation method and application of microencapsulated probiotics |
-
2021
- 2021-09-28 CN CN202111145201.7A patent/CN113583923B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104224851A (en) * | 2014-08-15 | 2014-12-24 | 任发政 | Application of bifidobacterium animalis subsp. lactis CGMCC NO.9273 |
| CN106722206A (en) * | 2017-01-09 | 2017-05-31 | 广州能靓生物技术有限公司 | A kind of composition for alleviating alimentary canal malaise symptoms and/or emotional stress and products thereof |
| CN109200064A (en) * | 2017-07-07 | 2019-01-15 | 中国农业大学 | The purposes of animal bifidobacteria A6 in medicine preparation |
| CN110810629A (en) * | 2018-08-07 | 2020-02-21 | 中国农业大学 | Probiotic preparation and application thereof |
| CN110305820A (en) * | 2019-08-19 | 2019-10-08 | 江南大学 | Lactobacillus rhamnosus CCFM1064 and its application |
| CN113150993A (en) * | 2021-02-01 | 2021-07-23 | 漯河微康生物科技有限公司 | Low-temperature spray drying preparation method and application of microencapsulated probiotics |
Non-Patent Citations (3)
| Title |
|---|
| Effect of Lactobacillus rhamnosus HN001 in Pregnancy on Postpartum Symptoms of Depression and Anxiety: A Randomised Double-blind Placebo-controlled Trial;R.F. Slykerman et al.;《EBioMedicine》;20170914;全文 * |
| Probiotic supplementation can positively affect anxiety and depressive symptoms: a systematic review of randomized controlled trials;Meysam Pirbaglou et al.;《NUTRITION RESEARCH》;20161231;全文 * |
| Probiotics for the treatment of depressive symptoms: An anti-inflammatory mechanism?;Caroline Park et al.;《Brain, Behavior, and Immunity》;20180718;全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113583923A (en) | 2021-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113583923B (en) | Probiotic composition and application thereof in preparation of medicine for treating constipation and depression | |
| Xavier-Santos et al. | Evidences and perspectives of the use of probiotics, prebiotics, synbiotics, and postbiotics as adjuvants for prevention and treatment of COVID-19: a bibliometric analysis and systematic review | |
| Majeed et al. | Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study | |
| Reid | The growth potential for dairy probiotics | |
| Magro et al. | Effect of yogurt containing polydextrose, Lactobacillus acidophilus NCFM and Bifidobacterium lactis HN019: a randomized, double-blind, controlled study in chronic constipation | |
| Guglielmetti et al. | Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life––a double‐blind, placebo‐controlled study | |
| Weichselbaum | Probiotics and health: a review of the evidence | |
| TWI594758B (en) | Composition comprising bifidobacteria,processes for the preparation thereof and uses thereof | |
| CN113855712B (en) | Composition capable of promoting defecation and application thereof | |
| CN104413334A (en) | Edible composition as well as preparation method and application thereof | |
| CN104740138A (en) | Composition containing aloe, probiotics and prebiotics and application of composition | |
| JP2009511469A (en) | Probiotics affecting fat metabolism and obesity | |
| CN116987608A (en) | Probiotic composition and application thereof in preparation of depression-complicated diarrhea-type irritable bowel syndrome medicines | |
| RU2725883C2 (en) | Composition for reducing intestinal gas production | |
| Wilson et al. | A systematic review of probiotics as a potential intervention to restore gut health in HIV infection | |
| JP7130287B2 (en) | Method for producing probiotic composition | |
| EP2209527A2 (en) | Probiotics for use in relieving symptoms associated with gastrointestinal disorders | |
| Hickson | Examining the evidence for the use of probiotics in clinical practice | |
| CN116426442B (en) | Probiotic capable of reducing body fat and improving antioxidant capacity and application thereof | |
| CN113750113A (en) | Composition of probiotics and prebiotics and application thereof | |
| JP2023096097A (en) | Combination of lactobacilli for the relief of irritable bowel syndrome and for the relief of other gastrointestinal disorders | |
| CN117535175A (en) | Composite probiotics and application thereof in preparation of products for preventing or assisting in treating colorectal cancer | |
| CN111214524A (en) | Application of ginseng fermented product | |
| Hong et al. | Study of the effect of Lactobacillus crispatus FSCDJY67L3 on Helicobacter Pylori eradication: a double-blind randomized controlled clinical trial | |
| JP7072966B2 (en) | Agents for preventing or ameliorating functional somatic syndrome and compositions containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |